Novo Nordisk (NVO) said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion for the higher 7.2-milligram dose of its weight-loss drug Wegovy or semaglutide.

The positive opinion was based on two trials, where the higher dose demonstrated an average weight loss of 20.7% at 72 weeks in people with obesity who do not have diabetes, the company said. The safety and tolerability profile is consistent with the approved 2.4 mg dose, Novo Nordisk added.

The 7.2 mg Wegovy dose could be available early in 2026, pending the European Commission's final approval, said Novo Nordisk executive vice president Ludovic Helfgott.

Novo Nordisk said the 7.2 mg Wegovy dose is also under review in the US, UK, and other countries.

Price: 50.46, Change: +0.16, Percent Change: +0.33